Twitter

Link your Twitter Account to Market Wire News


When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.


Be alerted of any news about your stocks and see what other stocks are trending.

home / news releases / GLYC - GlycoMimetics: Drug Approval Is Not Coming In 2024 But The Hype Could Be Real

GLYC - GlycoMimetics: Drug Approval Is Not Coming In 2024 But The Hype Could Be Real

GlycoMimetics Inc.

2024-01-30 13:04:10 ET

Summary

  • GlycoMimetics is developing molecules that target specific carbohydrate groups in the treatment of cancer.
  • The company's most advanced project, Uproleselan, has recently shown promising results in a phase 1b/2 study for patients with secondary AML.
  • GlycoMimetics has a strong pipeline of projects, but its success hinges on the outcome of a phase 3 trial, which carries significant risk.

Topline Summary and Update

For further details see:

GlycoMimetics: Drug Approval Is Not Coming In 2024, But The Hype Could Be Real
Stock Information
Company Name: GlycoMimetics Inc.
Stock Symbol: GLYC
Market: NASDAQ
Website: glycomimetics.com
Menu
GLYC GLYC Quote GLYC Short GLYC News GLYC Articles GLYC Message Board
Get GLYC Alerts

News, Short Squeeze, Breakout and More Instantly...